Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Trazodone Hydrochloride,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Granules India Gains ANDA approval for Trazodone Tablets
Details : Desyrel-Generic (trazodone hydrochloride) is a selective serotonin reuptake inhibitor indicated for the treatment of patients with major depressive disorder.
Product Name : Desyrel-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 08, 2024
Lead Product(s) : Trazodone Hydrochloride,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Trazodone Hydrochloride,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
PK Study of Diet Effect of Trazodone Hydrochloride Prolonged-Released Tablets in Healthy Chinese
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 30, 2016
Lead Product(s) : Trazodone Hydrochloride,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Trazodone Hydrochloride,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
PK Study of Multi-dose Trazodone Hydrochloride Prolonged-released Tablets in Healthy Chinese
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 30, 2016
Lead Product(s) : Trazodone Hydrochloride,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Trazodone Hydrochloride,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Clinical Study of Trazodone Hydrochloride Prolonged-Release Tablets for Treatment of Depression
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 02, 2012
Lead Product(s) : Trazodone Hydrochloride,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Trazodone Hydrochloride,Inapplicable
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : SocraTec R&D GmbH
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 14, 2025
Lead Product(s) : Trazodone Hydrochloride,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : SocraTec R&D GmbH
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Atomoxetin Hydrochloride,Trazodone Hydrochloride
Therapeutic Area : Sleep
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AD504 (Atomoxetine) showed a significant reduction of the Apnea Hypopnea Index (AHI) (from 18.2 [11.8 to 31.3] on placebo to 7.4 [5.4 to 16.1] events/h on AD504, p=0.024 and Hypoxic Burden (HB) from 46.3 [25.1 to 88.3] on placebo to 18.7 [14.9 to 43.5], ...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 06, 2022
Lead Product(s) : Atomoxetin Hydrochloride,Trazodone Hydrochloride
Therapeutic Area : Sleep
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Trazodone Hydrochloride,Inapplicable
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Cross Research S.A.
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 29, 2021
Lead Product(s) : Trazodone Hydrochloride,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Cross Research S.A.
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Atomoxetin Hydrochloride,Trazodone Hydrochloride
Therapeutic Area : Sleep
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AD504 (atomoxetine plus trazodone) showed a strong trend in the reduction in apnea hypopnea index (AHI) from placebo, which was the study’s primary endpoint.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 16, 2021
Lead Product(s) : Atomoxetin Hydrochloride,Trazodone Hydrochloride
Therapeutic Area : Sleep
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Esketamine Hydrochloride,Escitalopram Oxalate,Sertraline Hydrochloride,Duloxetine Hydrochloride,Mirtazapine,Agomelatine,Bupropion Hydrochloride,Trazodone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
February 25, 2019
Lead Product(s) : Esketamine Hydrochloride,Escitalopram Oxalate,Sertraline Hydrochloride,Duloxetine Hydrochloride,Mirtazapine,Agomelatine,Bupropion Hydrochloride,Trazodone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Trazodone Hydrochloride,Gabapentin
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Chiltern International
Deal Size : Inapplicable
Deal Type : Inapplicable
Trazodone/Gabapentin Fixed Dose Combination Products in Painful Diabetic Neuropathy
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 21, 2018
Lead Product(s) : Trazodone Hydrochloride,Gabapentin
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Chiltern International
Deal Size : Inapplicable
Deal Type : Inapplicable